Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.37 CHF | -4.87% | -0.11% | -4.49% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Mar. 27 | Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China | MT |
Sales 2023 * | 8.29M 9.08M | Sales 2024 * | 51.09M 55.99M | Capitalization | 86.34M 94.61M |
---|---|---|---|---|---|
Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 * | 10.4 x |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 1.69 x |
P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 46 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 70.73% |
Latest transcript on Santhera Pharmaceuticals Holding AG
1 day | -4.87% | ||
1 week | -0.11% | ||
Current month | -4.09% | ||
1 month | -1.06% | ||
3 months | -5.92% | ||
6 months | -22.94% | ||
Current year | -4.49% |
Managers | Title | Age | Since |
---|---|---|---|
Dario Eklund
CEO | Chief Executive Officer | 56 | 19-11-30 |
Thomas Meier
FOU | Founder | 62 | 04-09-06 |
Andrew P. Smith
DFI | Director of Finance/CFO | 61 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Meier
FOU | Founder | 62 | 04-09-06 |
Director/Board Member | 56 | 17-04-03 | |
Otto Schwarz
BRD | Director/Board Member | 68 | 23-06-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 9.37 | -4.87% | 27,670 |
24-04-17 | 9.85 | +8.36% | 43,661 |
24-04-16 | 9.09 | -0.11% | 16,324 |
24-04-15 | 9.1 | -1.62% | 22,324 |
24-04-12 | 9.25 | -1.39% | 15,950 |
Delayed Quote Swiss Exchange, April 18, 2024 at 11:30 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.49% | 99.51M | |
+11.18% | 9.08B | |
-15.94% | 4.57B | |
+18.47% | 3.9B | |
+1.89% | 3.69B | |
+28.61% | 2.62B | |
-24.63% | 2.34B | |
-29.37% | 2.14B | |
+2.55% | 1.84B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SANN Stock